AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02033408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB (antibiotics)
Description: 1. PO Vancomycin 250mgX4/d for 3 weeks~2. PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~3. PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug.
Study NCT02033408 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AB (antibiotics)
Description: 1. PO Vancomycin 250mgX4/d for 3 weeks~2. PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~3. PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug.
Study NCT02033408 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CS (corticosteroids) Only
Description: 1. methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~2. PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks
Study NCT02033408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CS (corticosteroids) Only
Description: 1. methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~2. PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks
Study NCT03624231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months
Study NCT03624231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab (75 mg) for up to 4 doses/cycles
Study NCT03624231 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy with 35 fractions (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks)
Study NCT02842307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual acupuncture implemented by senior acupuncturists
Description: Manual acupuncture once per day. No limitation on points, manipulations and time per session. Senior acupuncturists have to have more than 15 years of acupuncture clinical practice experience.
Study NCT02842307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual acupuncture implemented by junior acupuncturists
Description: Manual acupuncture once per day. No limitation on points, manipulations and time per session. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
Study NCT02842307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual acupuncture on P6 point
Description: Manual acupuncture implemented by junior acupuncturists once per day. P6 point, bilaterally, should achieve deqi sensation by even manipulations. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
Study NCT00804245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: needle biopsy
Description: Biopsy of positive findings found on CT scan
Study NCT00804245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET-CT scans supplemented with 11C-Choline tracer
Description: Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
Study NCT03401554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: titanium mesh
Description: closing the lateral window for maxillary sinus floor elevation with titanium mesh
Study NCT01972139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Angiography
Description: Subjects who met all criteria after the screening period did undergo a renal artery angiogram to evaluate renal artery anatomy. Only subjects with eligible renal artery anatomy were randomized.
Study NCT03178201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: Treatment will be self-administered on an outpatient basis. Patients will take TGR-1202 800 mg, oral, one tablet daily on a continuous basis. Each cycle lasts 28 days.
Study NCT03821207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The exercise group
Description: The students will make exercise during the first three days of the menstrual period
Study NCT03821207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The abdominal massage group
Description: The students will make abdominal massage during the first three days of the menstrual period
Study NCT03821207 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The students will nor massage or exercise
Study NCT00969254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pílulas de Lussen
Description: Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pílulas de Lussen®~\*\* Drug B: placebo.
Study NCT00969254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridium®
Description: Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pyridium®~\*\* Drug B: placebo.
Study NCT03867188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: A 25 gauge or larger bore needle will be used to inject the liposomal bupivacaine at the site of operation following the prescription guidelines provided by Exparel®. The maximum dose allowable for this study is 266mg or 20 mL as indicated in the FDA package insert.
Study NCT01763047 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: To be worn in a daily wear modality for a minimum of 6 hours per day.
Study NCT01763047 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: Lenses will be worn in a reuseable modality; cleaned and disinfected each night.
Study NCT05166174 — intervention group
Intervention type: PROCEDURE
Intervention: Transvaginal ultrasound in the third trimester pregnancy
Description: Ultrasonographic transvaginal exam in patients at third trimester pregnancy (34-38 weeks of gestation)
Study NCT01605136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: One 16mg subcutaneous implant every 2 months for 6 months.
Study NCT01605136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo subcutaneous implant every 2 months for 6 months
Study NCT04258774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Dioxide
Description: The study team will administer inhaled carbon dioxide to the participants during an MRI at a level
Study NCT00175435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Resiquimod gel
Description: 3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator
Study NCT03731234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance
Study NCT02321501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO
Study NCT02321501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT03401554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: collagen membrane
Description: closing the lateral window for maxillary sinus floor elevaion with collagen membrane
Study NCT00175435 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Resiquimod gel
Description: 3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
Study NCT02321501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02321501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02809443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5700
Description: GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
Study NCT04147962 — intervention group
Intervention type: DEVICE
Intervention: intense pulsed light (usual practice)
Description: collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light
Study NCT02057536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm A Directed exercise program
Study NCT02057536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Study NCT04501094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (M7824)
Description: 1200 mg administered intravenous (IV) every two weeks
Study NCT01997723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable monitoring
Description: A device applied over 1 arm (on the wrist and finger), worn overnight by patients to detect OSA.
Study NCT01997723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: One attended diagnostic sleep study.
Study NCT01997723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home portable monitoring
Description: Portable monitoring with WP200 device - applied by participants once at home.
Study NCT01997723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laboratory portable monitoring
Description: Portable monitoring with WP200 device - applied by technologist once in the laboratory simultaneously with polysomnography.
Study NCT01544517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)
Description: amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
Study NCT01544517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)
Description: amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
Study NCT04648007 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Kaihani Score
Description: Assessment of neuromodulatory chemicals in peripheral blood plasma samples.
Study NCT04709224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone Long-Acting Injectable
Description: Lumateperone Long-Acting Injectable
Study NCT02819869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin and Metformin use
Study NCT01768767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01768767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Study NCT01768767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine/Lithium
Study NCT03352310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous umbilical cord blood (UCB)
Description: autologous UCB transfusion to the newborn infants presence of HIE and/or anemia within 48 hours after the birth
Study NCT03352310 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard care
Description: standard care procedure to the newborn infants presence of HIE and/or anemia
Study NCT00801320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor collection
Description: Tumor collected at the time of planned surgery
Study NCT02754154 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Study NCT02754154 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Study NCT02754154 — intervention group
Intervention type: DRUG
Intervention: Dabigatran
Study NCT02754154 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Study NCT04737928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: latanoprost 0.05%(one drop, once daily)
Study NCT04737928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafluprost
Description: tafluprost 0.015% (one drop, once daily)
Study NCT03401736 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Ventilation
Description: Whether midazolam and dexmedetomidine have an effect on the diversity of intestinal microbiota or not is still unknown，especially the patient who requires the mechanical ventilation.
Study NCT03401736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Whether midazolam and dexmedetomidine have an effect on the diversity of intestinal microbiota or not is still unknown，especially the patient who requires the mechanical ventilation.
Study NCT03401736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The impact of Midazolam on the diversity of intestinal microbiota.
Study NCT03401736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The impact of dexmedetomidine on the diversity of intestinal microbiota.
Study NCT03675620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BFR
Description: Delfi's Personalized Tourniquet System for Blood Flow Restriction will be used with leg extension and leg press exercises. Bilateral thigh cuffs will be applied to the participants and occlusion pressure will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each participant will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between exercises. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
Study NCT03675620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation
Description: The control group will perform perform 4 sets of leg extensions and leg press (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
Study NCT02149719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Desensitisation using boiled peanut
Study NCT02149719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Desensitisation using boiled peanut (deferred start)
Study NCT00420589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taranabant
Description: taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
Study NCT00420589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Placebo capsules once daily. Treatment for 52 weeks
Study NCT03489265 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eluxadoline 100 mg
Description: 100 mg capsule-shaped tablet by mouth taken twice per day
Study NCT03489265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching capsule-shaped placebo tablets taken by mouth twice per day
Study NCT03235804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein, honey and yogurt.
Description: Participants will be asked to maintain their usual dietary intake and consume a powdered meal replacement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
Study NCT02516176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treadmill training
Description: Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
Study NCT06228807 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: The study involved a comparison of clinical characteristics, medical history, laboratory biomarkers, echocardiographic measurements, angiographic findings, and clinical outcomes between two groups.
Description: Differences in clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic findings, coronary microvascular function using caIMR and clinical outcomes were assessed between the two groups to identify potential risk factors. Subsequently, the incidence of clinical outcomes and mortality was compared. Univariate logistic regression and multivariate logistic regression analyses, adjusted for significant risk factors, were conducted to identify independent predictive factors. Finally, a Receiver Operating Characteristic (ROC) curve was generated, and the area under the curve was evaluated to assess the predictive accuracy of the regression model.
Study NCT02392156 — intervention group
Intervention type: BIOLOGICAL
Intervention: rFVIIIFc
Description: As described in the treatment arm
Study NCT02392156 — intervention group
Intervention type: BIOLOGICAL
Intervention: rFIXFc
Description: As described in the treatment arm
Study NCT02392156 — intervention group
Intervention type: DRUG
Intervention: non-Fc FVIII replacement products
Description: Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
Study NCT02392156 — intervention group
Intervention type: DRUG
Intervention: non-Fc FIX replacement products
Description: Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
Study NCT02870270 — intervention group
Intervention type: OTHER
Intervention: Cancer treatment
Description: Patients undergoing treatment for cancer in the head and neck region
Study NCT02750709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.
Study NCT04145440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR202
Description: Patients received 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occured weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
Study NCT04164641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic
Description: Physical therapy evaluation (range of motion, strength, mobility, scale). Noraxon based gait assessment on treadmill while barefoot and with instrumented inner soles. Over ground walking assessment (with wireless instrumented inner soles, observational gait analysis while climbing stairs, ramps, curbs). Noraxon gait assessment and walking on treadmill will be video recorded for assessment. Standard measure of functionality and 6 minute walk test will be conducted. Patient will be fitted with corrective orthotics, based on usual care. Physical therapy re-evaluation. Noraxon based gait assessment and foot assessment (any areas of irritation, callus formation, swelling, ulcer formation, and gait mobility irregularities will be monitored and reassessed) throughout the study.
Study NCT04006743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The swaddling group
Description: The newborns were placed in a supine position on a 90 cm2 soft fabric for swaddling procedure. The upper side of the bandage was aligned with the shoulder of the newborn. Newborns' arms were put in a flexion position. The top of the body was completely covered with a bandage. The infant's head can move freely. The swaddling procedure took about one minute. In the study, swaddling process was applied 10 minutes before the painful procedure. The swaddled newborns remained in the swaddling during the procedure and for 5 minutes after the procedure.
Study NCT04006743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The expressed breast milk group
Description: In terms of the reliability of the study results, nothing was orally given to the preterm infant at least 30 minutes before the procedure. As recommended in the studies, 2 ml oral breast milk was given to preterm infants before the procedure. In the study, breast milk was given slowly to the upper part of the tongue of each preterm infant from his/her own mother as a single dose before OGT insertion. As a result, preterm was ensured to take all of 2 ml breast milk by reducing the aspiration risk of breastmilk. The breast milk was given without touching the tip of the injector to the newborn's mouth. The preterm infants were not allowed to suck the tip of the injector.
Study NCT00603395 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ReCap Total Hip Resurfacing System
Description: This is a hip resurfacing system.
Study NCT03184012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuSmile Zirconia crowns by NuSmile company
Description: anterior carious teeth restored with Zirconia crowns
Study NCT04006743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The facilitated tucking group
Description: Facilitated tucking was given in supine position by holding the arm and legs of the preterm infant to the body by the researcher. In line with the literature, facilitated tucking was initiated 3 minutes before OGT insertion in order for the newborn to feel the fetal position and to cope with the painful procedure. The preterm was kept in fetal position during the procedure and for 5 minutes after the procedure.